211At labelled Substance P (5 –11) as potential radiopharmaceutical for glioma treatment
The purpose of the present work was to label Substance P (5 –11) with 211At using a rhodium(III) complex with a bifunctional ligand – 2-(1,5,9,13-tetrathiacyclohexadecan-3-yloxy)acetic acid ([16aneS4]-COOH) and to assess the in vitro stability and toxicity of the obtained radiobioconjugate. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 25, 2017 Category: Nuclear Medicine Authors: Monika Lyczko, Marek Pruszynski, Agnieszka Majkowska-Pilip, Krzysztof Lyczko, Bogdan Was, Sylwia Meczynska-Wielgosz, Marcin Kruszewski, Katarzyna Szkliniarz, Jerzy Jastrzebski, Anna Stolarz, Aleksander Bilewicz Source Type: research
99mTc-labeled PSMA inhibitor: Biokinetics and Radiation Dosimetry in Healthy Subjects and Imaging of Prostate Cancer Tumors in Patients
The prostate-specific membrane antigen (PSMA) is expressed in epithelial cells of the prostate and highly overexpressed in 95% of advanced prostate cancers. The aim of this study was to estimate the biokinetics and dosimetry of 99mTc-EDDA/HYNIC-iPSMA (99mTc-labeled PSMA inhibitor) in eight healthy subjects and evaluate its usefulness as a tumor-imaging agent in eight prostate cancer patients. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 25, 2017 Category: Nuclear Medicine Authors: Clara Santos-Cuevas, Jenny Davanzo, Guillermina Ferro-Flores, Francisco O. Garc ía-Pérez, Blanca Ocampo-García, Eleazar Ignacio-Alvarez, Edgar Gómez-Argumosa, Martha Pedraza-López Source Type: research
131I –labeled Chitosan Hydrogels for Radioembolization: A preclinical Study in Small Animals
The purpose of the study was to examine potential of 131I –labeled chitosan hydrogels (Chi) for treatment of liver cancer. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 25, 2017 Category: Nuclear Medicine Authors: Hyosook Hwang, Kwang Il Kim, JeongIl Kwon, Byoung Soo Kim, Hwan-Seok Jeong, Su Jin Jang, Phil-Sun Oh, Ho Sung Park, Seok Tae Lim, Myung-Hee Sohn, Hwan-Jeong Jeong Source Type: research
[11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice
[11C]Erlotinib PET has shown promise to distinguish non-small cell lung cancer (NSCLC) tumors harboring the activating epidermal growth factor receptor (EGFR) mutation delE746-A750 from tumors with wild-type EGFR. To assess the suitability of [11C]erlotinib PET to detect the emergence of acquired erlotinib resistance in initially erlotinib-responsive tumors, we performed in vitro binding and PET experiments in mice bearing tumor xenografts using a range of different cancer cells, which were erlotinib-sensitive or exhibited clinically relevant resistance mechanisms to erlotinib. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 25, 2017 Category: Nuclear Medicine Authors: Alexander Traxl, Taraneh Beikbaghban, Thomas Wanek, Kushtrim Kryeziu, Christine Pirker, Severin Mairinger, Johann Stanek, Thomas Filip, Michael Sauberer, Claudia Kuntner, Walter Berger, Oliver Langer Source Type: research
Baseline And Longitudinal Variability Of Normal Tissue Uptake Values Of [18F]-fluorothymidine-PET Images
This study aimed to quantitatively investigate baseline tracer uptake of blood pool, lung, liver and bone marrow and their precision, and to assess the longitudinal effect of systemic treatment on biodistribution. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 10, 2017 Category: Nuclear Medicine Authors: MCF Cysouw, GM Kramer, V Frings, AJ De Langen, MJ Wondergem, LM Kenny, EO Aboagye, C Kobe, J Wolf, OS Hoekstra, R. Boellaard Source Type: research
Synthesis, radiolabeling and preclinical evaluation of a [11C]GMOM derivative as PET radiotracer for the ion channel of the N-methyl-D-aspartate receptor
Presently available PET ligands for the NMDAr ion channel generally suffer from fast metabolism. The purpose of this study was to develop a metabolically more stable ligand for the NMDAr ion channel, taking [11C]GMOM ([11C]1) as the lead compound. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 8, 2017 Category: Nuclear Medicine Authors: Pieter J Klein, Robert C Schuit, Athanasios Metaxas, Johannes AM Christiaans, Esther Kooijman, Adriaan A Lammertsma, Bart NM van Berckel, Albert D Windhorst Source Type: research
Preparation and evaluation of L- and D-5-[18F]fluorotryptophan as PET imaging probes for indoleamine and tryptophan 2,3-dioxygenases
Indoleamine and tryptophan 2,3-dioxygenases (IDO1 and TDO2) are pyrrolases catalyzing the oxidative cleavage of the 2,3-double bond of L-tryptophan in kynurenine pathway. In the tumor microenvironment, their increased activity prevents normal immune function, i.e. tumor cell recognition and elimination by cytotoxic T-cells. Consequently, inhibition of the kynurenine pathway may enhance the activity of cancer immunotherapeutics by reversing immune dysfunction. We sought to investigate the properties of radiolabeled 5-[18F]fluorotryptophan with respect to its ability for measuring IDO1 and TDO2 activity by positron emission ...
Source: Nuclear Medicine and Biology - May 5, 2017 Category: Nuclear Medicine Authors: Tang Tang, Herman S. Gill, Annie Ogasawara, Jeff N. Tinianow, Alexander N. Vanderbilt, Simon-Peter Williams, Georgia Hatzivassiliou, Sharla White, Wendy Sandoval, Kevin DeMent, Mengling Wong, Jan Marik Source Type: research
VPAC1 Targeted 64Cu-TP3805 kit preparation and its evaluation
Previously, our laboratory has shown that 64Cu-TP3805 can specifically target VPAC1 receptors and be used for positron emission tomography (PET) imaging of breast (BC) and prostate cancer (PC) in humans. Present work is aimed at the formulation of a freeze-dried diaminedithiol-peptide (N2S2-TP3805) kit and it's evaluation for the preparation of 64Cu labeled TP3805. Parameters such as pH, temperature and incubation time were examined that influenced the radiolabeling efficiency and stability of the product. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 3, 2017 Category: Nuclear Medicine Authors: Sushil K. Tripathi, Pardeep Kumar, Edouard J. Trabulsi, Sung Kim, Peter A. McCue, Charles Intenzo, Adam Berger, Leonard Gomella, Mathew L. Thakur Source Type: research
VAPC-1 Targeted 64Cu-TP3805 kit preparation and its evaluation
Previously, our laboratory has shown that 64Cu-TP3805 can specifically target VPAC-1 receptors and be used for Positron Emission Tomography (PET) imaging of breast (BC) and prostate cancer (PC) in humans. Present work is aimed at the formulation of a freeze-dried diaminedithiol-peptide (N2S2-TP3805) kit and it's evaluation for the preparation of 64Cu labeled TP3805. Parameters such as pH, temperature and incubation time were examined that influenced the radiolabeling efficiency and stability of the product. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 3, 2017 Category: Nuclear Medicine Authors: Sushil K. Tripathi, Pardeep Kumar, Edouard J. Trabulsi, Sung Kim, Peter McCue, Charles Intenzo, Adam Berger, Leonard Gomella, Mathew L. Thakur Source Type: research
Editorial Board
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 2, 2017 Category: Nuclear Medicine Source Type: research
Table of Contents
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - May 2, 2017 Category: Nuclear Medicine Source Type: research
Editorial Board
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - April 28, 2017 Category: Nuclear Medicine Source Type: research
Table of Contents
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - April 28, 2017 Category: Nuclear Medicine Source Type: research
Regiospecific radiolabelling of Nanofitin on Ni Magnetic Beads with [18F]FBEM and in vivo PET studies
Nanofitins are low molecular weight, single chain and cysteine-free protein scaffolds able to selectively bind a defined biological target. They derive from Sac7d bacterial protein family and are highly stable over a wide range of pH (0 –13) and temperature (Tm ~80°C). Their extreme stability, low cost of production and high tolerability for chemical coupling make Nanofitins a very interesting alternative to antibodies and their fragments. Here, a hexahistidine tagged model Nanofitin (H4) directed against hen egg white lysozyme was radiolabelled and injected in mice to provide a baseline biodistribution and pharmacokine...
Source: Nuclear Medicine and Biology - April 27, 2017 Category: Nuclear Medicine Authors: S. Dammicco, M. Goux, C. Lemaire, G. Becker, M.A. Bahri, A. Plenevaux, M. Cinier, A. Luxen Source Type: research
Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution
Alpha-emitting radionuclides have gained considerable attention as payloads for cancer targeting molecules due to their high cytotoxicity. One attractive radionuclide for this purpose is 212Pb, which by itself is a β-emitter, but acts as an in vivo generator for its short-lived α-emitting daughters. The standard method of preparing 212Pb-labeled antibodies requires handling and evaporation of strong acids containing high radioactivity levels by the end user. An operationally easier and more rapid process cou ld be useful since the 10.6h half-life of 212Pb puts time constraints on the preparation protocol. (Source: Nuclea...
Source: Nuclear Medicine and Biology - April 26, 2017 Category: Nuclear Medicine Authors: Sara Westr øm, Roman Generalov, Tina B. Bønsdorff, Roy H. Larsen Source Type: research
